<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Inborn errors of metabolism: Epidemiology, pathogenesis, and clinical features</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">V Reid Sutton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sihoun Hahn, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Congenital metabolic disorders result from the absence or abnormality of an enzyme or its cofactor, leading to either accumulation or deficiency of a specific metabolite  (<a class="graphic graphic_table graphicRef82924" href="/d/graphic/82924.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef56040" href="/d/graphic/56040.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef69937" href="/d/graphic/69937.html" rel="external">table 3</a> and <a class="graphic graphic_table graphicRef74261" href="/d/graphic/74261.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef63392" href="/d/graphic/63392.html" rel="external">table 5</a> and <a class="graphic graphic_table graphicRef114663" href="/d/graphic/114663.html" rel="external">table 6</a>). Most of these disorders are transmitted as autosomal recessive traits.</p><p>The possibility of an inborn error of metabolism (IEM) should be considered in infants, children, and adults who present with any of the clinical or laboratory features discussed below or in the topic review on metabolic emergencies, particularly if the findings remain unexplained after standard evaluation [<a href="#rid1">1-6</a>]. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a> and <a class="local">'Age at presentation'</a> below.)</p><p>Optimal outcome for children with IEM depends upon early recognition of the signs and symptoms of metabolic disease and prompt evaluation and referral to a center familiar with the management of these disorders [<a href="#rid7">7</a>]. Delay in diagnosis may result in acute metabolic decompensation, progressive neurologic injury, or death.</p><p>The epidemiology, pathogenesis, and most common chronic clinical and laboratory manifestations of IEM are discussed below. The presentation, initial diagnosis, and management of IEM presenting as metabolic emergencies are discussed in detail separately. The major classes of IEM and their characteristic clinical and biochemical features are described elsewhere, as is a diagnostic approach to identifying the specific IEM. In addition, many of the individual disorders are covered in separate topic reviews (see specific topic reviews). (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a> and  <a class="medical medical_review" href="/d/html/2930.html" rel="external">"Inborn errors of metabolism: Classification"</a> and  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder"</a>.)</p><p class="headingAnchor" id="H3709423"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Individual IEM are rare disorders, most having an incidence of less than 1 per 100,000 births. However, when considered collectively, the incidence may approach 1 in 800 to 1 in 2500 births [<a href="#rid8">8,9</a>]. In one review of cases of IEM diagnosed in British Columbia (a predominantly White population) between 1969 and 1996, estimates of incidence of various classes of disorders were as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>Amino acid disorders (excluding phenylketonuria) – 7.6 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage diseases – 7.6 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Phenylketonuria – 7.5 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Organic acidemias – 3.7 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Peroxisomal disorders – 3.5 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial diseases – 3.2 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen storage diseases – 2.3 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Urea cycle diseases – 1.9 per 100,000</p><p></p><p>In another review of cases of IEM diagnosed in the West Midlands of the United Kingdom (where approximately 11 percent of the population is from Black and underrepresented ethnic groups), the frequency of selected IEM during 1999 to 2003 was as follows [<a href="#rid9">9</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial diseases – 20.3 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage diseases – 19.3 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Amino acid disorders (excluding phenylketonuria) – 18.7 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Organic acidemias – 12.6 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Phenylketonuria – 8.1 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Peroxisomal disorders – 7.4 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen storage diseases – 6.8 per 100,000</p><p class="bulletIndent1"><span class="glyph">●</span>Urea cycle diseases – 4.5 per 100,000</p><p></p><p>The greater incidence of disorders in the West Midlands study may be related to differences in the ethnicity of the populations, diagnostic methods and approaches among laboratories and countries, and improved technology, reporting, and awareness of some disorders (eg, mitochondrial disorders) over time.</p><p class="headingAnchor" id="H3709430"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Metabolic disorders can be caused by several mechanisms. Most metabolic disorders are caused by a single enzyme deficiency that disrupts one step of a metabolic pathway. This disruption may lead to the accumulation of metabolites preceding the interrupted step, as in alkaptonuria, or the inability to make certain intermediates or end products of a specific metabolic pathway, such as ketoacids during fasting in patients with medium-chain acyl-CoA dehydrogenase (MCAD) deficiency [<a href="#rid5">5</a>].</p><p>Less frequently, alterations that result in abnormalities of more than one enzyme can affect several metabolic steps. An example is multiple sulfatase deficiency, a lysosomal storage disorder that is caused by impaired posttranslational modification of sulfatases. Disorders of cofactors also can affect multiple enzymes. As an example, defects of cobalamin (vitamin B12) transport and synthesis may lead to accumulation of both methylmalonic acid and homocysteine. (See  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>.)</p><p>In most cases, a specific metabolic disorder is caused by a defect in one specific gene. However, a single enzyme, such as mitochondrial trifunctional protein, can be composed of multiple subunits encoded by different genes and catalyze more than one metabolic reaction. In addition, defects in different enzymes can result in a similar clinical phenotype (eg, elevated total plasma homocysteine may result from either deficiency of the enzyme cystathionine beta-synthase or from a cobalamin processing defect [complementation group G]).</p><p class="headingAnchor" id="H4"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical manifestations of IEM may include findings in virtually every system. Neurologic and gastrointestinal manifestations are the most frequent. The presenting features of IEM may be acute or chronic. Acute signs include episodic vomiting accompanied by dehydration or shock, lethargy and coma, rhabdomyolysis, and hypoglycemia associated with minor illnesses, stress, or a prolonged fast. Chronic signs of metabolic disease include growth delay/failure to thrive, hepatomegaly, cardiomyopathy, spastic diplegia, and developmental delay or regression.</p><p>Clinical presentations of metabolic emergencies, including recurrent vomiting and dehydration, lethargy and coma, seizures, and sudden infant death syndrome (SIDS) or apparent life-threatening event (ALTE), are discussed separately. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Clinical presentations'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Neurologic</span><span class="headingEndMark"> — </span>Neurologic manifestations of IEM include lethargy, coma, seizures, developmental delay or regression, peripheral neuropathy, abnormalities of tone, motor problems, ataxia, and neuropsychiatric manifestations.</p><p class="headingAnchor" id="H14590174"><span class="h3">Lethargy, coma, and seizures</span><span class="headingEndMark"> — </span>These neurologic presentations of IEM are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Lethargy and coma'</a> and  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Seizures'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Developmental delay</span><span class="headingEndMark"> — </span>It is estimated that IEM are the underlying cause in only 1 to 5 percent of cases of developmental delay [<a href="#rid10">10,11</a>]. However, developmental delay and/or intellectual disability, particularly with progressive worsening, may occur in many IEM. Thus, it is important to evaluate the possibility of IEM as an underlying cause to provide accurate prognosis, genetic counseling, and specific therapy, if available [<a href="#rid10">10,12,13</a>]. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Developmental delay'</a> and  <a class="medical medical_review" href="/d/html/615.html" rel="external">"Developmental-behavioral surveillance and screening in primary care", section on 'Follow-up'</a> and  <a class="medical medical_review" href="/d/html/6189.html" rel="external">"Intellectual disability in children: Evaluation for a cause", section on 'Metabolic testing'</a>.)</p><p>Developmental delay and intellectual disability are most commonly associated with the following metabolic disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of urea cycle and amino acid metabolism  (<a class="graphic graphic_figure graphicRef73454" href="/d/graphic/73454.html" rel="external">figure 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Organic acidemias  (<a class="graphic graphic_table graphicRef81144" href="/d/graphic/81144.html" rel="external">table 7</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of creatine metabolism (see  <a class="medical medical_review" href="/d/html/97126.html" rel="external">"Congenital disorders of creatine synthesis and transport"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Peroxisomal disorders  (<a class="graphic graphic_table graphicRef74261" href="/d/graphic/74261.html" rel="external">table 4</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage disorders  (<a class="graphic graphic_table graphicRef63392" href="/d/graphic/63392.html" rel="external">table 5</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial disorders and disorders of oxidative phosphorylation</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital disorders of protein glycosylation</p><p></p><p>Associated clinical findings may provide a clue to the underlying IEM. As examples, a family history of hearing loss and diabetes with maternal transmission in a patient with developmental delay is typical of a mitochondrial disorder, while spastic diplegia with developmental delay is suggestive of argininemia. Boolean searches of electronic resources, such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fomim&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F1mEzbrra1EyPWuMKBWRSz2FZxizAt9vS6osbKh7UCRu&amp;TOPIC_ID=2936" target="_blank">Online Mendelian Inheritance in Man</a>, using the signs and symptoms of an individual patient can be used to generate a differential diagnosis of IEM that could cause the observed signs and symptoms. Another website for IEM allows Boolean searches [<a href="#rid14">14</a>], while a different diagnostic app groups diseases based upon the general metabolic defect or type of clinical presentation but does not for allow Boolean searches [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Neuropathy</span><span class="headingEndMark"> — </span>Peripheral neuropathy may be a feature of disorders of vitamin B12 (cobalamin) transport and processing, lysosomal disorders  (<a class="graphic graphic_table graphicRef63392" href="/d/graphic/63392.html" rel="external">table 5</a>), and certain mitochondrial disorders. (See  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Lysosomal diseases'</a> and  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Mitochondrial disorders'</a> and  <a class="medical medical_review" href="/d/html/6166.html" rel="external">"Overview of acquired peripheral neuropathies in children", section on 'Vitamin deficiency or excess'</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Abnormal tone</span><span class="headingEndMark"> — </span>Hypotonia may be a manifestation of fatty acid oxidation disorders, mitochondrial disorders, urea cycle defects, peroxisomal disorders, lysosomal acid maltase deficiency (Pompe disease, glycogen storage disease II), and Smith-Lemli-Opitz syndrome (a disorder of cholesterol biosynthesis) [<a href="#rid4">4,16</a>]. (See  <a class="medical medical_review" href="/d/html/6148.html" rel="external">"Approach to the infant with hypotonia and weakness"</a> and  <a class="medical medical_review" href="/d/html/2929.html" rel="external">"Urea cycle disorders: Clinical features and diagnosis"</a>.)</p><p>Spastic diplegia may occur in arginase deficiency [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/d/html/2929.html" rel="external">"Urea cycle disorders: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Myopathy</span><span class="headingEndMark"> — </span>Myopathy and rhabdomyolysis can occur in lysosomal and nonlysosomal glycogen storage diseases, disorders of fatty acid oxidation, and mitochondrial disorders. Patients may complain of exercise intolerance, muscle pain, and cramps rather than weakness. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Skeletal myopathy'</a> and  <a class="medical medical_review" href="/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a> and  <a class="medical medical_review" href="/d/html/2941.html" rel="external">"Overview of inherited disorders of glucose and glycogen metabolism"</a> and  <a class="medical medical_review" href="/d/html/111790.html" rel="external">"Overview of fatty acid oxidation disorders"</a> and  <a class="medical medical_review" href="/d/html/115918.html" rel="external">"Specific fatty acid oxidation disorders"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Ataxia and dystonia</span><span class="headingEndMark"> — </span>Ataxia may be a manifestation of peroxisomal disorders, mitochondrial disorders, disorders of metal metabolism, and lysosomal storage disorders. Ataxia associated with a dysplastic cerebellum is seen in congenital disorders of glycosylation. (See  <a class="medical medical_review" href="/d/html/6147.html" rel="external">"Peroxisomal disorders"</a> and  <a class="medical medical_review" href="/d/html/6226.html" rel="external">"Neuropathies associated with hereditary disorders", section on 'Mitochondrial disorders'</a> and  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Mitochondrial ataxias'</a> and  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Sialidosis'</a>.)</p><p>Dystonia may be a feature of mitochondrial disorders or organic acidurias after a metabolic crisis associated with damage to the basal ganglia [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/d/html/4886.html" rel="external">"Etiology, clinical features, and diagnostic evaluation of dystonia"</a> and  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>.)</p><p class="headingAnchor" id="H16"><span class="h3">Neuropsychiatric</span><span class="headingEndMark"> — </span>IEM may present with psychiatric or behavioral manifestations, such as [<a href="#rid10">10,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Self-injurious behavior in Lesch-Nyhan syndrome (see  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased activity and aggression in Sanfilippo syndrome and other mucopolysaccharidoses (see  <a class="medical medical_review" href="/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Personality changes, deteriorating school performance, depression, paranoia, or catatonia in Wilson disease (see  <a class="medical medical_review" href="/d/html/3626.html" rel="external">"Wilson disease: Epidemiology and pathogenesis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychosis in some patients with adult Tay-Sachs disease, homocystinuria, the porphyrias, and purine disorders</p><p></p><p class="headingAnchor" id="H17"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Gastrointestinal presentations of IEM include recurrent episodes of vomiting or dehydration, poor feeding, failure to thrive, decreased gastrointestinal motility, hepatomegaly or hepatosplenomegaly, and jaundice [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H14590181"><span class="h3">Vomiting and poor feeding</span><span class="headingEndMark"> — </span>Recurrent vomiting, poor feeding, and associated dehydration are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Gastrointestinal and feeding problems'</a>.)</p><p class="headingAnchor" id="H19"><span class="h3">Organomegaly</span><span class="headingEndMark"> — </span>Hepatomegaly and/or splenomegaly can be seen in the following conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen storage diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage diseases (Gaucher, Niemann-Pick)</p><p class="bulletIndent1"><span class="glyph">●</span>Galactosemia</p><p class="bulletIndent1"><span class="glyph">●</span>Peroxisomal disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Tyrosinemia type 1</p><p class="bulletIndent1"><span class="glyph">●</span>Bile acid disorders</p><p class="bulletIndent1"><span class="glyph">●</span>Congenital disorders of glycosylation (also referred to as carbohydrate-deficient glycoprotein syndromes)</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal acid lipase deficiency (Wolman disease/cholesteryl ester storage disorder) [<a href="#rid19">19</a>]</p><p></p><p>Hepatosplenomegaly and isolated splenomegaly occur primarily in lysosomal storage disorders [<a href="#rid20">20</a>], whereas isolated hepatomegaly is more typical of glycogen storage diseases and certain mitochondrial diseases. In addition, signs or symptoms that accompany hepatosplenomegaly may suggest a particular diagnosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly with hypoglycemia and poor growth is suggestive of glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease), glycogen debrancher deficiency (glycogen storage disease III, Cori disease, Forbes disease), disorders of gluconeogenesis, or severe hyperinsulinism. (See  <a class="medical medical_review" href="/d/html/5805.html" rel="external">"Approach to hypoglycemia in infants and children"</a> and  <a class="medical medical_review" href="/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children"</a> and  <a class="medical medical_review" href="/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a> and  <a class="medical medical_review" href="/d/html/2906.html" rel="external">"Glycogen debrancher deficiency (glycogen storage disease III, Cori disease)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly with liver failure suggests hereditary fructose intolerance, galactosemia, tyrosinemia type 1, neonatal hemochromatosis, a mitochondrial disorder, or Wilson disease [<a href="#rid3">3,16</a>]. (See  <a class="medical medical_review" href="/d/html/5801.html" rel="external">"Causes of hypoglycemia in infants and children"</a> and  <a class="medical medical_review" href="/d/html/2928.html" rel="external">"Galactosemia: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism"</a> and  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Gestational alloimmune liver disease (neonatal hemochromatosis)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gaucher disease should be suspected in a child of Ashkenazi Jewish ancestry with anemia and thrombocytopenia in addition to hepatosplenomegaly. (See  <a class="medical medical_review" href="/d/html/2918.html" rel="external">"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="headingAnchor" id="H20"><span class="h3">Jaundice</span><span class="headingEndMark"> — </span>Cholestatic jaundice may be a manifestation of galactosemia, citrin deficiency, alpha-1 antitrypsin deficiency, disorders of bile acid metabolism, transaldolase deficiency, peroxisomal disorders, Niemann-Pick disease, neonatal hemochromatosis, and congenital disorders of glycosylation [<a href="#rid16">16</a>]. (See  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants"</a>.)</p><p class="headingAnchor" id="H21"><span class="h2">Cardiomyopathy</span><span class="headingEndMark"> — </span>Hypertrophic or dilated cardiomyopathy may occur in several IEM and is typically related to impaired energy metabolism or storage material. Hypertrophic cardiomyopathy occurs in lysosomal acid maltase deficiency (glycogen storage disease type II, Pompe disease) and in the mucopolysaccharidoses. Dilated cardiomyopathy can occur in fatty acid oxidation disorders, organic acidemias, and mitochondrial disorders (eg, disorders of oxidative phosphorylation). (See  <a class="medical medical_review" href="/d/html/6197.html" rel="external">"Metabolic myopathies caused by disorders of lipid and purine metabolism"</a> and  <a class="medical medical_review" href="/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a> and  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'Cardiomyopathy'</a>.)</p><p class="headingAnchor" id="H22"><span class="h2">Dysmorphic features</span><span class="headingEndMark"> — </span>Dysmorphic features may be present at birth or may develop with age in a number of IEM, including [<a href="#rid20">20-22</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Peroxisomal disorders (eg, high forehead, large anterior fontanelle, hypoplastic supraorbital ridges, epicanthal folds, low and broad nasal bridge, high-arched palate, and deformed ear lobes in Zellweger syndrome)  (<a class="graphic graphic_picture graphicRef72662" href="/d/graphic/72662.html" rel="external">picture 1</a>) (see  <a class="medical medical_review" href="/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Zellweger spectrum disorders'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage diseases (eg, coarse facial features may be present at birth in mucolipidosis II and monosialotetrahexosylganglioside (GM1) gangliosidosis; in other mucopolysaccharidoses, coarsening of the facial features develops with age) (see  <a class="medical medical_review" href="/d/html/2931.html" rel="external">"Mucopolysaccharidoses: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Homocystinuria due to cystathionine-beta-synthetase deficiency (long face and lanky body habitus [Marfanoid phenotype])</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Smith-Lemli-Opitz syndrome (cleft palate, congenital heart disease, hypospadias, polydactyly, and syndactyly)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital disorders of protein glycosylation (see  <a class="medical medical_review" href="/d/html/112030.html" rel="external">"Overview of congenital disorders of glycosylation"</a> and  <a class="medical medical_review" href="/d/html/126336.html" rel="external">"Specific congenital disorders of glycosylation"</a>)</p><p></p><p class="headingAnchor" id="H24"><span class="h2">Ophthalmologic</span><span class="headingEndMark"> — </span>Ophthalmologic presentations of IEM include cataracts, corneal opacities or clouding  (<a class="graphic graphic_picture graphicRef52924" href="/d/graphic/52924.html" rel="external">picture 2</a>), cherry-red spots  (<a class="graphic graphic_picture graphicRef65650" href="/d/graphic/65650.html" rel="external">picture 3</a>), retinitis pigmentosa  (<a class="graphic graphic_picture graphicRef81281" href="/d/graphic/81281.html" rel="external">picture 4</a>), and dislocated lenses  (<a class="graphic graphic_table graphicRef64851" href="/d/graphic/64851.html" rel="external">table 8</a>) [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/6270.html" rel="external">"Cataract in children"</a> and  <a class="medical medical_review" href="/d/html/6264.html" rel="external">"Ectopia lentis (dislocated lens) in children"</a> and  <a class="medical medical_review" href="/d/html/6905.html" rel="external">"Retinitis pigmentosa: Clinical presentation and diagnosis"</a>.)</p><p class="headingAnchor" id="H25"><span class="h2">Dermatologic</span><span class="headingEndMark"> — </span>Dermatologic manifestations of IEM may include [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Rashes – Acrodermatitis enteropathica  (<a class="graphic graphic_picture graphicRef71329" href="/d/graphic/71329.html" rel="external">picture 5</a>), biotinidase deficiency, methylmalonic acidemia, propionic acidemia (see  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Photosensitivity – Porphyrias, Hartnup disease (see  <a class="medical medical_review" href="/d/html/7101.html" rel="external">"Porphyrias: An overview"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperkeratosis and ichthyosis  (<a class="graphic graphic_picture graphicRef66723" href="/d/graphic/66723.html" rel="external">picture 6</a>) – Tyrosinemia type II, Sjögren-Larsson syndrome, steroid-sulfatase deficiency, multiple sulfatase deficiency, congenital disorders of glycosylation, Refsum disease (adult form) (see  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Hereditary tyrosinemia type 2'</a> and  <a class="medical medical_review" href="/d/html/1699.html" rel="external">"Sjögren-Larsson syndrome"</a> and  <a class="medical medical_review" href="/d/html/6147.html" rel="external">"Peroxisomal disorders", section on 'Refsum disease'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin ulceration – Prolidase deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin nodules – Farber disease, congenital disorders of protein glycosylation (see  <a class="medical medical_review" href="/d/html/112030.html" rel="external">"Overview of congenital disorders of glycosylation"</a> and  <a class="medical medical_review" href="/d/html/126336.html" rel="external">"Specific congenital disorders of glycosylation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Angiokeratoma – Fabry disease and other lysosomal storage diseases  (<a class="graphic graphic_picture graphicRef81624 graphicRef71039" href="/d/graphic/81624.html" rel="external">picture 7A-B</a>) (see  <a class="medical medical_review" href="/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pearly papules – Mucopolysaccharidosis (MPS) II (Hunter syndrome)  (<a class="graphic graphic_picture graphicRef65695" href="/d/graphic/65695.html" rel="external">picture 8</a>) [<a href="#rid24">24,25</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypopigmentation – Untreated phenylketonuria (see  <a class="medical medical_review" href="/d/html/2919.html" rel="external">"Overview of phenylketonuria"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Melanocytic nevi (formerly known as "Mongolian spots") – Lysosomal storage diseases such as Hurler syndrome (mucopolysaccharidosis type I Hurler [MPS I H]) and GM1 gangliosidosis type 1  (<a class="graphic graphic_picture graphicRef77805" href="/d/graphic/77805.html" rel="external">picture 9</a>) [<a href="#rid26">26</a>]</p><p></p><p class="headingAnchor" id="H26"><span class="h2">Hydrops fetalis</span><span class="headingEndMark"> — </span>Nonimmune hydrops fetalis (abnormal fetal fluid collections) may occur in the following IEM  (<a class="graphic graphic_table graphicRef57407" href="/d/graphic/57407.html" rel="external">table 9</a>) [<a href="#rid27">27-29</a>] (see  <a class="medical medical_review" href="/d/html/6794.html" rel="external">"Nonimmune hydrops fetalis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Lysosomal storage diseases, including, but not limited to Gaucher disease, MPS types IV and VII, GM1 gangliosidosis, Niemann-Pick disease type C, Farber disease, infantile-free sialic acid storage disease, sialidosis, galactosialidosis, mucolipidosis type II (I cell disease) (see appropriate topic reviews)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neonatal hemochromatosis [<a href="#rid30">30</a>] (see  <a class="medical medical_review" href="/d/html/5945.html" rel="external">"Causes of cholestasis in neonates and young infants", section on 'Gestational alloimmune liver disease (neonatal hemochromatosis)'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mitochondrial respiratory chain disorders [<a href="#rid31">31</a>] (see  <a class="medical medical_review" href="/d/html/5151.html" rel="external">"Mitochondrial myopathies: Clinical features and diagnosis"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital disorders of glycosylation [<a href="#rid32">32</a>] (see  <a class="medical medical_review" href="/d/html/112030.html" rel="external">"Overview of congenital disorders of glycosylation"</a> and  <a class="medical medical_review" href="/d/html/126336.html" rel="external">"Specific congenital disorders of glycosylation"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease) [<a href="#rid33">33</a>] (see  <a class="medical medical_review" href="/d/html/2937.html" rel="external">"Glycogen branching enzyme deficiency (glycogen storage disease IV, Andersen disease)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Red blood cell (RBC) enzyme abnormalities (glucose-6-phosphate dehydrogenase deficiency, pyruvate kinase deficiency, and glucose phosphate isomerase deficiency) (see  <a class="medical medical_review" href="/d/html/7111.html" rel="external">"Diagnosis and management of glucose-6-phosphate dehydrogenase (G6PD) deficiency"</a> and  <a class="medical medical_review" href="/d/html/7129.html" rel="external">"Pyruvate kinase deficiency"</a> and  <a class="medical medical_review" href="/d/html/7128.html" rel="external">"Rare RBC enzyme disorders"</a>)</p><p></p><p class="headingAnchor" id="H2366118"><span class="h2">Abnormal odors</span><span class="headingEndMark"> — </span>Abnormal odor of the patient's breath, urine  (<a class="graphic graphic_table graphicRef74441" href="/d/graphic/74441.html" rel="external">table 10</a>), perspiration, saliva, or cerumen should prompt consideration of organic acidemias, amino acid disorders, urea cycle defects, and fatty acid oxidation disorders [<a href="#rid6">6,20,34</a>]. However, the majority of patients who have an unusual odor do not have an IEM or other underlying medical cause for the odor.</p><p>Odors characteristic of selected disorders are listed below [<a href="#rid3">3,6,20,34</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Burnt sugar, curry, or maple syrup – Maple syrup urine disease (fenugreek, a spice commonly used in Asian cooking; artificial maple syrup; and herbal teas contain sotolon, which can result in a maple syrup smell when consumed)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sweaty socks or cheese-like – Isovaleric acidemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fruity, ammoniacal – Methylmalonic acidemia or propionic acidemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mouse urine, musty – Phenylketonuria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cabbage-like, rotten eggs – Tyrosinemia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malt or hops – Methionine malabsorption</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cat urine – 3-methylcrotonic acidemia, 3-hydroxy-3-methylglutaric aciduria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Fish-like – Trimethylaminuria and carnitine excess</p><p></p><p class="headingAnchor" id="H27"><span class="h2">Urine changes</span><span class="headingEndMark"> — </span>Abnormal urine color or odor may be suggestive of IEM  (<a class="graphic graphic_table graphicRef74441" href="/d/graphic/74441.html" rel="external">table 10</a>). Color changes may only be apparent after the urine stands for some time (permitting oxidation). This is particularly true for alkaptonuria and, in the era of flush toilets and disposable diapers, explains why the diagnosis is rarely made until later in life. (See  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism", section on 'Alkaptonuria'</a>.)</p><p class="headingAnchor" id="H11382266"><span class="h1">AGE AT PRESENTATION</span><span class="headingEndMark"> — </span>Initial symptoms of metabolic diseases may occur in any age group, from fetuses and newborns to people in their seventh decade of life [<a href="#rid35">35</a>]. The onset and severity may be influenced by changes in dietary intake, fasting, dehydration, intercurrent illness, medications, strenuous activity, childbirth, trauma, or surgery [<a href="#rid1">1</a>]. The presenting signs and symptoms of some disorders may vary with age. (See  <a class="medical medical_review" href="/d/html/17216.html" rel="external">"Inborn errors of metabolism: Identifying the specific disorder", section on 'History'</a>.)</p><p>As an example, the typical presentation of urea cycle disorders or organic acidemias in newborns is an acute, severe illness characterized by lethargy, poor feeding, vomiting, and shock. However, less severe forms of these disorders may present in older children or adults with episodes of vomiting and lethargy, failure to thrive, protein intolerance, seizures, or psychomotor abnormalities. (See  <a class="medical medical_review" href="/d/html/2929.html" rel="external">"Urea cycle disorders: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a> and  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a>.)</p><p>In neonates, the age at the time of presentation may be helpful in narrowing down the specific category of IEM, although there are exceptions [<a href="#rid4">4</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Nonketotic hyperglycinemia, urea cycle disorders, and branched-chain organic acidemias often present with life-threatening illness between 12 and 72 hours of age, whereas maple syrup urine disease usually presents later in the first week. However, mild forms of all IEM exist, and many patients may have the first metabolic decompensation anywhere from 1 to 60 years of age. Parturition is an especially dangerous time for women with undiagnosed IEM. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In neonates with acute liver failure, neonatal hemochromatosis usually presents during the first week, galactosemia in the first or second week, tyrosinemia type 1 any time after the first week, and alpha-1 antitrypsin deficiency, Niemann-Pick disease, and bile acid synthesis defects after the third week. Mitochondrial disorders may present at any time. (See  <a class="medical medical_review" href="/d/html/16142.html" rel="external">"Acute liver failure in children: Etiology and evaluation", section on 'Inherited metabolic disease'</a>.)</p><p></p><p class="headingAnchor" id="H28"><span class="h1">LABORATORY FINDINGS</span><span class="headingEndMark"> — </span>The possibility of an IEM should be considered in infants, children, and adults who present with otherwise unexplained acid-base disorders, hyperammonemia, hypoglycemia, hematologic abnormalities, liver dysfunction, and kidney disease. In some disorders, the laboratory abnormalities may be present only during an acute presentation. Thus, for example, a normal plasma ammonia level in an individual who is not acutely ill does <strong>not</strong> rule out a metabolic disorder.</p><p class="headingAnchor" id="H14590188"><span class="h2">Acid-base disorders, hyperammonemia, and hypoglycemia</span><span class="headingEndMark"> — </span>Acid-base disorders (including lactic acidosis), hyperammonemia, and hypoglycemia associated with IEM are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Laboratory findings'</a>.)</p><p class="headingAnchor" id="H32"><span class="h2">Hematologic abnormalities</span><span class="headingEndMark"> — </span>Hematologic manifestations of IEM may involve any or all of the cell lines, as described below [<a href="#rid3">3</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Macrocytic anemia – Homocystinuria, methylmalonic acidemia, hereditary orotic aciduria, lysinuric protein intolerance (a disorder of amino acid transport), Lesch-Nyhan syndrome (see  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a> and  <a class="medical medical_review" href="/d/html/6232.html" rel="external">"Hyperkinetic movement disorders in children", section on 'Lesch-Nyhan syndrome'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Normocytic anemia – Neonatal hemochromatosis, disorders associated with severe liver failure, Wilson disease, porphyria, Wolman disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, orotic aciduria, erythropoietic glycolytic enzyme deficiency (eg, pyruvate kinase, phosphofructokinase, glucose-6-phosphate dehydrogenase) (see appropriate topic reviews)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predominant or isolated neutropenia – Glycogen storage disease type Ib, lysinuric protein intolerance, hereditary orotic aciduria, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, mevalonic aciduria (see  <a class="medical medical_review" href="/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)"</a> and  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Predominant thrombocytopenia – Cobalamin metabolism defect (Cbl C), methylmalonic acidemia, propionic acidemia, isovaleric acidemia (see  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pancytopenia – Gaucher disease, methylmalonic acidemia, propionic acidemia, isovaleric acidemia, mevalonic aciduria, lysinuric protein intolerance (see  <a class="medical medical_review" href="/d/html/2918.html" rel="external">"Gaucher disease: Pathogenesis, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects"</a>)</p><p></p><p class="headingAnchor" id="H33"><span class="h2">Liver abnormalities</span><span class="headingEndMark"> — </span>IEM may be associated with hyperammonemia and jaundice. In addition, IEM that are associated with liver failure also may result in bleeding diathesis (eg, tyrosinemia type 1, glutaric aciduria type I). (See  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Hyperammonemia'</a> and <a class="local">'Jaundice'</a> above and  <a class="medical medical_review" href="/d/html/2935.html" rel="external">"Disorders of tyrosine metabolism"</a> and  <a class="medical medical_review" href="/d/html/2927.html" rel="external">"Organic acidemias: An overview and specific defects", section on 'Glutaric acidemia type 1'</a>.)</p><p class="headingAnchor" id="H34"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Kidney disease accompanies several IEM. The spectrum of kidney disease may include [<a href="#rid3">3,18</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Renal Fanconi syndrome – Tyrosinemia type I, cystinosis, mitochondrial respiratory chain disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal tubular acidosis – Pyruvate carboxylase deficiency, methylmalonic aciduria, carnitine palmitoyl transferase I deficiency (see  <a class="medical medical_review" href="/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nephrolithiasis – Cystinuria, gout and other purine disorders, hyperoxaluria, hereditary renal hypouricemia, Lesch-Nyhan syndrome</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal cysts – Multiple acyl-CoA dehydrogenase deficiency (glutaric acidemia type II), neonatal carnitine palmitoyltransferase type II (CPT II) deficiency, peroxisomal disorders</p><p></p><p class="headingAnchor" id="H3795771879"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120233.html" rel="external">"Society guideline links: Inborn errors of metabolism"</a>.)</p><p class="headingAnchor" id="H36"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Individual inborn errors of metabolism (IEM) are rare disorders, most having an incidence of less than 1 per 100,000 births. However, the collective incidence may approach 1 in 800 to 1 in 2500 births. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Most metabolic disorders are caused by a single enzyme deficiency that disrupts one step of a metabolic pathway. Less frequently, alterations that result in abnormalities of more than one enzyme can affect several metabolic steps. Disorders of cofactors also can affect multiple enzymes. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1">An individual metabolic disorder is usually caused by a defect in a single gene. However, a single enzyme can be composed of multiple subunits encoded by different genes and can catalyze more than one metabolic reaction, with subunit defects resulting in different phenotypes. In addition, defects in different enzymes can result in a similar clinical phenotype.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation and triggers</strong> - Congenital metabolic diseases  (<a class="graphic graphic_table graphicRef82924" href="/d/graphic/82924.html" rel="external">table 1</a>) can present in newborns, infants, children, or adults. The onset and severity may be influenced by changes in dietary intake, fasting, dehydration, intercurrent illness, medications, strenuous activity, childbirth, trauma, or surgery. The signs and symptoms vary depending upon the age and disorder. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic and gastrointestinal manifestations</strong> – Neurologic and gastrointestinal symptoms and signs are the most common presenting features of IEM. Neurologic features of IEM include lethargy, coma, seizures, developmental delay or regression, peripheral neuropathy, abnormalities of tone, weakness, ataxia, and neuropsychiatric manifestations. Exercise intolerance, muscle pain, or muscle cramps rather than weakness may be the presenting complaint in patients with metabolic myopathies. Gastrointestinal presentations of IEM include recurrent episodes of vomiting, diarrhea, organomegaly, and jaundice. (See <a class="local">'Neurologic'</a> above and <a class="local">'Gastrointestinal'</a> above and  <a class="medical medical_review" href="/d/html/6193.html" rel="external">"Approach to the metabolic myopathies"</a> and  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Clinical presentations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory abnormalities</strong> – Laboratory presentations of IEM include acid-base disorders (including lactic acidosis), hyperammonemia, hypoglycemia, anemia, neutropenia, thrombocytopenia, and abnormalities of liver function (eg, hyperbilirubinemia, elevated transaminases, coagulopathy). In some disorders, the laboratory abnormalities may be present only during an acute presentation. Thus, for example, a normal plasma ammonia level in an individual who is not acutely ill does <strong>not</strong> rule out a metabolic disorder. (See <a class="local">'Laboratory findings'</a> above and  <a class="medical medical_review" href="/d/html/2912.html" rel="external">"Metabolic emergencies in suspected inborn errors of metabolism: Presentation, evaluation, and management", section on 'Laboratory findings'</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.</li><li><a class="nounderline abstract_t">Maestri NE, Clissold D, Brusilow SW. Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis. J Pediatr 1999; 134:268.</a></li><li class="breakAll">Saudubray JM, Charpentier C. Clinical phenotypes: Diagnosis/algorithms. In: Metabolic and molecular bases of inherited disease, Scriver CR, Beaudet AL, Sly WS, Valle D (Eds), McGraw-Hill, New York 2001. p.1327.</li><li><a class="nounderline abstract_t">Leonard JV, Morris AA. Diagnosis and early management of inborn errors of metabolism presenting around the time of birth. Acta Paediatr 2006; 95:6.</a></li><li><a class="nounderline abstract_t">Lindor NM, Karnes PS. Initial assessment of infants and children with suspected inborn errors of metabolism. Mayo Clin Proc 1995; 70:987.</a></li><li><a class="nounderline abstract_t">Wappner RS. Biochemical diagnosis of genetic diseases. Pediatr Ann 1993; 22:282.</a></li><li><a class="nounderline abstract_t">Champion MP. An approach to the diagnosis of inherited metabolic disease. Arch Dis Child Educ Pract Ed 2010; 95:40.</a></li><li><a class="nounderline abstract_t">Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105:e10.</a></li><li><a class="nounderline abstract_t">Sanderson S, Green A, Preece MA, Burton H. The incidence of inherited metabolic disorders in the West Midlands, UK. Arch Dis Child 2006; 91:896.</a></li><li><a class="nounderline abstract_t">Cleary MA, Green A. Developmental delay: when to suspect and how to investigate for an inborn error of metabolism. Arch Dis Child 2005; 90:1128.</a></li><li><a class="nounderline abstract_t">Curry CJ, Stevenson RE, Aughton D, et al. Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics. Am J Med Genet 1997; 72:468.</a></li><li><a class="nounderline abstract_t">Powell K, Van Naarden Braun K, Singh R, et al. Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism. J Pediatr 2010; 156:420.</a></li><li class="breakAll">Treatable intellectual disability. An interactive tool for the clinician. http://www.treatable-id.org/.</li><li class="breakAll">Inborn Errors of Metabolism Knowledgebase iembase.org.</li><li class="breakAll">Vademecum Metabolicum http://www.vademetab.org/.</li><li class="breakAll">De Vivo DC, DiMauro S. Hereditary and acquired types of myopathy. In: Oski's pediatrics. Principles and practice, 3rd ed, McMillan JA, DeAngelis CD, Feigin RD, Warshaw JB (Eds), Lippincott, Williams and Wilkins, Philadelphia 1999. p.1971.</li><li><a class="nounderline abstract_t">Scheuerle AE, McVie R, Beaudet AL, Shapira SK. Arginase deficiency presenting as cerebral palsy. Pediatrics 1993; 91:995.</a></li><li class="breakAll">Wappner RS, Hainline BE. Introduction to inborn errors of metabolism. In: Oski's pediatrics. Principles and practice, 4th ed, McMillan JA, Feigin RD, DeAngelis C, Jones MD (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.2145.</li><li><a class="nounderline abstract_t">Zhang B, Porto AF. Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency. J Pediatr Gastroenterol Nutr 2013; 56:682.</a></li><li><a class="nounderline abstract_t">Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics 1998; 102:E69.</a></li><li><a class="nounderline abstract_t">Cormier-Daire V, Rustin P, Rötig A, et al. Craniofacial anomalies and malformations in respiratory chain deficiency. Am J Med Genet 1996; 66:457.</a></li><li><a class="nounderline abstract_t">von Kleist-Retzow JC, Cormier-Daire V, Viot G, et al. Antenatal manifestations of mitochondrial respiratory chain deficiency. J Pediatr 2003; 143:208.</a></li><li><a class="nounderline abstract_t">Poll-The BT, Maillette de Buy Wenniger-Prick CJ. The eye in metabolic diseases: clues to diagnosis. Eur J Paediatr Neurol 2011; 15:197.</a></li><li><a class="nounderline abstract_t">Demitsu T, Kakurai M, Okubo Y, et al. Skin eruption as the presenting sign of Hunter syndrome IIB. Clin Exp Dermatol 1999; 24:179.</a></li><li><a class="nounderline abstract_t">Prystowsky SD, Maumenee IH, Freeman RG, et al. A cutaneous marker in the Hunter syndrome a report of four cases. Arch Dermatol 1977; 113:602.</a></li><li><a class="nounderline abstract_t">Hackbart BA, Arita JH, Pinho RS, et al. Mongolian spots are not always a benign sign. J Pediatr 2013; 162:1070.</a></li><li><a class="nounderline abstract_t">Van Maldergem L, Jauniaux E, Fourneau C, Gillerot Y. Genetic causes of hydrops fetalis. Pediatrics 1992; 89:81.</a></li><li><a class="nounderline abstract_t">Stone DL, Sidransky E. Hydrops fetalis: lysosomal storage disorders in extremis. Adv Pediatr 1999; 46:409.</a></li><li><a class="nounderline abstract_t">Kattner E, Schäfer A, Harzer K. Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease. Eur J Pediatr 1997; 156:292.</a></li><li><a class="nounderline abstract_t">Wisser J, Schreiner M, Diem H, Roithmeier A. Neonatal hemochromatosis: a rare cause of nonimmune hydrops fetalis and fetal anemia. Fetal Diagn Ther 1993; 8:273.</a></li><li><a class="nounderline abstract_t">Fayon M, Lamireau T, Bioulac-Sage P, et al. Fatal neonatal liver failure and mitochondrial cytopathy: an observation with antenatal ascites. Gastroenterology 1992; 103:1332.</a></li><li><a class="nounderline abstract_t">de Koning TJ, Toet M, Dorland L, et al. Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome. J Inherit Metab Dis 1998; 21:681.</a></li><li><a class="nounderline abstract_t">Alegria A, Martins E, Dias M, et al. Glycogen storage disease type IV presenting as hydrops fetalis. J Inherit Metab Dis 1999; 22:330.</a></li><li><a class="nounderline abstract_t">Mace JW, Goodman SI, Centerwall WR, Chinnock RF. The child with an unusual odor. A clinical resumé. Clin Pediatr (Phila) 1976; 15:57.</a></li><li><a class="nounderline abstract_t">Ahrens-Nicklas RC, Slap G, Ficicioglu C. Adolescent presentations of inborn errors of metabolism. J Adolesc Health 2015; 56:477.</a></li></ol></div><div id="topicVersionRevision">Topic 2936 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Weiner DL. Metabolic emergencies. In: Textbook of pediatric emergency medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott, Williams and Wilkins, Philadelphia 2006. p.1193.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064660" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10064660" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Neonatal onset ornithine transcarbamylase deficiency: A retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16373289" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Diagnosis and early management of inborn errors of metabolism presenting around the time of birth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7564553" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Initial assessment of infants and children with suspected inborn errors of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8510995" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Biochemical diagnosis of genetic diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351150" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : An approach to the diagnosis of inherited metabolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10617747" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Incidence of inborn errors of metabolism in British Columbia, 1969-1996.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16690699" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The incidence of inherited metabolic disorders in the West Midlands, UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16243864" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Developmental delay: when to suspect and how to investigate for an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9375733" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Evaluation of mental retardation: recommendations of a Consensus Conference: American College of Medical Genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914633" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914633" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914633" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914633" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19914633" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of developmental disabilities and receipt of special education services among children with an inborn error of metabolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8474825" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Arginase deficiency presenting as cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8474825" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Arginase deficiency presenting as cerebral palsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23403440" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cholesteryl ester storage disease: protean presentations of lysosomal acid lipase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832597" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Inborn errors of metabolism in infancy: a guide to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8989468" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Craniofacial anomalies and malformations in respiratory chain deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12970634" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Antenatal manifestations of mitochondrial respiratory chain deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21511505" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The eye in metabolic diseases: clues to diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354174" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Skin eruption as the presenting sign of Hunter syndrome IIB.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/404968" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A cutaneous marker in the Hunter syndrome a report of four cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23374678" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mongolian spots are not always a benign sign.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1728027" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Genetic causes of hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10645471" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Hydrops fetalis: lysosomal storage disorders in extremis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9128814" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8260082" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neonatal hemochromatosis: a rare cause of nonimmune hydrops fetalis and fetal anemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1397893" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Fatal neonatal liver failure and mitochondrial cytopathy: an observation with antenatal ascites.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9762608" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Recurrent nonimmune hydrops fetalis associated with carbohydrate-deficient glycoprotein syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10384399" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Glycogen storage disease type IV presenting as hydrops fetalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/812627" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The child with an unusual odor. A clinical resumé.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907648" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Adolescent presentations of inborn errors of metabolism.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
